Phyllanthin

Synonyms: 叶下珠脂素
Phyllanthin 是一种口服有效的抗癌剂,可抑制 MOLT-4 细胞活力、增加细胞凋亡并抑制细胞迁移和侵袭,通过抑制 ALK5 和 Smad2/3 下调 TGF 信号通路发挥抗纤维化作用,同时还具有抗炎和抗菌特性。
产品编号: MS-Q40452 纯度: 99.97% CAS No.: 10351-88-9 分子式: C24H34O6 分子量: 418.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Phyllanthin 是一种口服有效的抗癌剂,可抑制 MOLT-4 细胞活力、增加细胞凋亡并抑制细胞迁移和侵袭,通过抑制 ALK5 和 Smad2/3 下调 TGF 信号通路发挥抗纤维化作用,同时还具有抗炎和抗菌特性。

生物实验数据

生物活性 Phyllanthin is an orally active anticancer agent that inhibits MOLT-4 cell viability, increases apoptosis, and suppresses cell migration and invasion, exerts antifibrotic effects by downregulating the TGF signaling pathway through inhibition of ALK5 and Smad2/3, and also possesses anti-inflammatory and antibacterial properties.
IC50 & Target

Inhibits TGF-β1 with inhibition constant of 33.15 mM.

体外研究
(In Vitro)

Phyllanthin (1.56, 6.25 和 25 μM; 2 小时) 在 U937 巨噬细胞中抑制了脂多糖 (MS-X54539) 诱导的促炎反应。
Phyllanthin (5-100 μM/mL; 24 小时) 抑制 MOLT-4 白血病癌细胞生长,IC50 为 25 µM/mL,诱导细胞凋亡。
Phyllanthin 预测发现可通过抑制刺突糖蛋白和主要蛋白酶发挥较强的抗 COVID-19 活性。

Cell Viability Assay

Cell Line: U937 macrophages, MOLT-4 cells and normal MS‐5 cells
Concentration: 1.56, 3.12, 6.25, 12.5, and 25 μM (U937 macrophages);
5, 10, 25, 50, 75, and 100 μM/mL (MOLT-4 cells and normal MS‐5 cells)
Incubation Time: 24 h
Result: No effect on the viability of U937 macrophages and MS‐5 cells.
Reduced cell viability of MOLT-4 in a dose-dependent manner.

Western Blot Analysis

Cell Line: LPS (1 μg/mL) (HY- D1056) treated U937 macrophages for 30 min
Concentration: 1.56, 6.25, and 25 μM
Incubation Time: 2 h
Result: Inhibited phosphorylation levels of IKKα/β, p65 and IκBα in a concentration‐dependent manner.
Suppressed LPS‐stimulated activation of JNK, ERK, p38 and AKT in a concentration‐dependent manner.

Real Time qPCR

Cell Line: LPS (1 μg/mL) (HY- D1056) treated U937 macrophages for 1 day
Concentration: 1.56, 6.25 and 25 μM
Incubation Time: 2 h
Result: Dose-dependently suppressed the increased TNF‐α mRNA level at concentrations of 1.25, 6.25 and 25 μM.
Significantly suppressed IL‐1β gene expression at concentrations of 6.25 and 25 μM.
体内研究
(In Vivo)

Phyllanthin (10 mg/kg; 口服; 每天一次; 30天) 在四氯化碳 (MS-X51453) 诱导的肝毒性和实验性肝纤维化小鼠模型中具有保护作用。
Phyllanthin (30 mg/kg; 口服; 单次) 在亚硝基二乙胺 (MS-J31233) 诱导的大鼠肝癌模型中具有抗癌作用。
Phyllanthin (20-100 mg/kg; 口服; 每天一次; 14天) 在 Balb/C 小鼠模型中对细胞和体液免疫反应具有抑制作用。

Animal Model: Carbon tetrachloride (MS-X51453) treated Swiss strain female mice (32-35 g)
Dosage: 10 mg/kg
Administration: Oral administration (p.o.); once a day; 30 days
Result: Normalized the level of liver marker enzymes (ALT and AST) and collagen content in hepatotoxicity and experimental liver fibrosis mice.
Restored normal liver architecture, reversed the formation of continuous fibrotic septa between the central and portal veins and nodules.
Reduced the levels of TGF-β1, ALK5, p-Smad2 and p-Smad3 in hepatotoxicity and experimental liver fibrosis mice.
Animal Model: Diethylnitrosamine (Cat. No. MS-J31233) treated male Wistar albino rats (210-230 g)
Dosage: 30 mg/kg
Administration: Oral administration (p.o.); single dose
Result: Significantly reduced 8-OHdG levels and delayed the oxidative damage in diethylnitrosamine -induced liver cancer rats.
Significantly reduced liver tissue injury biomarkers (ALT, AST, GGT, ALP and LDH) levels and tumor markers (AFP and CEA).
Reduced cellular enlargement, nodules, and hyperplasiaenlargement in diethylnitrosamine-induced liver tissue.
Animal Model: Male Balb/C mice aged 6-8 weeks old (18-22 g)
Dosage: 20 mg/kg, 40 mg/kg, and 100 mg/kg
Administration: Oral administration (p.o.); once a day; 14 days
Result: Dose-dependently inhibited CD11b/CD18 adhesion, the engulfment of E.coli by peritoneal macrophages molecules, NO and MPO release.
Dose-dependently inhibited T and B lymphocytes proliferation and down-regulated Th1 (IL-2 and IFN-γ) and Th2 (IL-4) cytokines.
Dose-dependently inhibited the sheep red blood cell (sRBC)-induced swelling rate of mice paw in delayed type hypersensitivity.
Significantly inhibited the serum levels of ceruloplasmin and lysozyme at higher doses (40 and 100 mg/kg).
Dose-dependently down-regulated anti-sRBC immunoglobulins (IgM and IgG) antibody titer.
性状 固体
颜色 White to off-white

化学信息

分子量 418.52
分子式 C24H34O6
CAS No. 10351-88-9
别名 叶下珠脂素

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.78 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 62.5 mg/mL (149.34 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.3894 mL11.9469 mL23.8937 mL59.7343 mL
5 mM0.4779 mL2.3894 mL4.7787 mL11.9469 mL
10 mM0.2389 mL1.1947 mL2.3894 mL5.9734 mL
15 mM0.1593 mL0.7965 mL1.5929 mL3.9823 mL
20 mM0.1195 mL0.5973 mL1.1947 mL2.9867 mL
25 mM0.0956 mL0.4779 mL0.9557 mL2.3894 mL
30 mM0.0796 mL0.3982 mL0.7965 mL1.9911 mL
40 mM0.0597 mL0.2987 mL0.5973 mL1.4934 mL
50 mM0.0478 mL0.2389 mL0.4779 mL1.1947 mL
60 mM0.0398 mL0.1991 mL0.3982 mL0.9956 mL
80 mM0.0299 mL0.1493 mL0.2987 mL0.7467 mL
100 mM0.0239 mL0.1195 mL0.2389 mL0.5973 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础